Japan Q3 Roundup: Majors Enjoy Forex Windfall But COVID Returns Decline
Mainstays Mostly Strong
While the weaker yen boosted the top line for Japanese pharma companies with a strong global presence in the fiscal first half, it also raised reported costs. Several firms reported strong growth for mainstays, while holding out high hopes for selected new drugs with blockbuster potential. But some other products underperformed for unexpected reasons.
